✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
Long-Acting GHRH Analogue
Also known as CJC-1295 DAC / hGRF(1-29) bioconjugate
CJC-1295 with DAC is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) bearing a Drug Affinity Complex that extends its half-life, studied in research on the GH/IGF-1 axis.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
CJC-1295 with DAC is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) bearing a Drug Affinity Complex that extends its half-life, studied in research on the GH/IGF-1 axis.
Experimental models examine prolonged GHRH-receptor stimulation and downstream secretory dynamics.
Third-party tested for purity, ID, quantity.
CJC-1295 with DAC couples a tetrasubstituted GHRH(1-29) analogue to a maleimide group that binds serum albumin, markedly prolonging its circulating half-life. Research has examined sustained stimulation of growth-hormone and IGF-1 secretion in controlled studies.
Investigations evaluate the kinetics of GH release and IGF-1 elevation under structured experimental conditions.
CJC-1295 was developed from research into albumin-binding bioconjugates designed to extend the activity of short-lived GHRH peptides.
Early clinical pharmacology characterized its prolonged stimulation of the GH/IGF-1 axis, distinguishing the DAC-bearing form from shorter-acting analogues.
Research into CJC-1295 with DAC focuses on GHRH-receptor signaling and GH/IGF-1 axis kinetics. Frameworks evaluate albumin-binding half-life extension and secretory dynamics under controlled clinical and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of cjc 1295 with dac. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
PubMedOnce-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
PubMedPulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$50.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$60.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$90.00
